Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALUR NASDAQ:MBOT NASDAQ:NTRB NASDAQ:VANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.11+0.3%$2.63$1.98▼$22.25$16.34M-0.461.19 million shs29,145 shsMBOTMicrobot Medical$3.53-6.0%$2.93$0.82▼$4.62$160.56M1.223.12 million shs1.50 million shsNTRBNutriband$6.43+4.1%$7.52$3.72▼$11.78$71.64M1.13136,819 shs106,155 shsVANIVivani Medical$1.16$1.35$0.91▼$1.80$68.72M3.12103,623 shs14,429 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies-3.47%-4.36%-24.46%-27.60%-87.35%MBOTMicrobot Medical-1.57%-3.35%+47.06%+35.87%+326.14%NTRBNutriband-4.64%-4.34%-16.51%-24.57%+51.23%VANIVivani Medical+0.87%-3.33%-12.78%+3.57%-11.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALURAllurion Technologies2.7156 of 5 stars3.45.00.00.02.20.00.6MBOTMicrobot Medical2.0847 of 5 stars3.33.00.00.02.50.00.6NTRBNutriband2.7367 of 5 stars3.53.00.00.02.31.70.6VANIVivani Medical3.0256 of 5 stars3.55.00.00.02.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 2.80Moderate Buy$22.83984.20% UpsideMBOTMicrobot Medical 2.50Moderate Buy$9.00155.32% UpsideNTRBNutriband 3.00Buy$13.00102.33% UpsideVANIVivani Medical 3.00Buy$4.00244.83% UpsideCurrent Analyst Ratings BreakdownLatest ALUR, VANI, NTRB, and MBOT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.008/21/2025MBOTMicrobot MedicalZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/12/2025ALURAllurion TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$32.11M0.51N/AN/A($8.24) per share-0.26MBOTMicrobot MedicalN/AN/AN/AN/A$0.67 per shareN/ANTRBNutriband$2.14M33.48N/AN/A$0.58 per share11.08VANIVivani MedicalN/AN/AN/AN/A$0.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$7.20M-$12.53N/AN/AN/A-158.30%N/A-59.91%11/12/2025 (Estimated)MBOTMicrobot Medical-$11.44M-$0.58N/AN/AN/AN/A-76.27%-67.54%11/12/2025 (Estimated)NTRBNutriband-$10.48M-$0.90N/AN/AN/A-415.93%-68.25%-60.40%N/AVANIVivani Medical-$23.49M-$0.45N/AN/AN/AN/A-194.66%-68.64%11/12/2025 (Estimated)Latest ALUR, VANI, NTRB, and MBOT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025ALURAllurion Technologies-$0.65-$0.57+$0.08-$1.28$6.20 million$3.38 million8/13/2025Q2 2025VANIVivani Medical-$0.10-$0.12-$0.02-$0.12N/AN/A8/12/2025Q2 2025MBOTMicrobot Medical-$0.08-$0.10-$0.02-$0.10$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.021.70MBOTMicrobot MedicalN/A12.0612.06NTRBNutriband0.013.713.48VANIVivani MedicalN/A1.301.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%MBOTMicrobot Medical16.30%NTRBNutriband19.70%VANIVivani Medical6.78%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies9.60%MBOTMicrobot Medical4.74%NTRBNutriband54.09%VANIVivani Medical46.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.76 million7.02 millionOptionableMBOTMicrobot Medical2045.55 million43.39 millionOptionableNTRBNutriband1011.15 million5.12 millionNot OptionableVANIVivani Medical2059.24 million31.76 millionOptionableALUR, VANI, NTRB, and MBOT HeadlinesRecent News About These CompaniesA brewing GLP-1 showdown, from Big Pharma pills to a biotech implantAugust 27, 2025 | finance.yahoo.comOzempic for dogs? I’d happily put my food-obsessed golden retriever on ‘Wagovy’August 24, 2025 | aol.comAAre weight-loss jabs for dogs the next big thing? Scientists exploring new solutions for pet obesityAugust 22, 2025 | msn.comOzempic For Pets: New Drug Being Tested For Animal Obesity - Here's What We KnowAugust 22, 2025 | msn.comCould Dogs Get Their Version Of Ozempic? Scientists Test "Ozempup" For Pet ObesityAugust 21, 2025 | ndtv.comNAfter Ozempic, is “Ozempup” on the way? Scientists explore weight-loss jabs for obese pet dogs-- All details hereAugust 21, 2025 | msn.comVivani Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference on Innovative Drug Implant TechnologyAugust 20, 2025 | quiverquant.comQVivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025August 20, 2025 | globenewswire.comFido get fat? Ozempic for dogs could hit the market in three yearsAugust 19, 2025 | msn.comVivani Medical (NASDAQ:VANI) Stock Price Down 0.8% After Earnings MissAugust 15, 2025 | marketbeat.comVivani Medical (NASDAQ:VANI) Announces Quarterly Earnings ResultsAugust 15, 2025 | marketbeat.comVivani closes $10M financing, advances GLP-1 implantAugust 14, 2025 | drugdeliverybusiness.comDVivani Medical, Inc.: Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deVivani Medical Reports Q2 2025 Results and $10M FinancingAugust 13, 2025 | tipranks.comVivani Medical Provides Business Update Including $10M Equity Financing and Reports Second ...August 13, 2025 | bakersfield.comBVivani Medical Secures $10M Through Share Purchase AgreementAugust 13, 2025 | msn.comVivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comVivani Medical (VANI) to Release Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.com3 Penny Stocks With Market Caps Over $30M To ConsiderJuly 16, 2025 | finance.yahoo.comVivani Medical Insiders Added US$5.29m Of Stock To Their HoldingsJune 30, 2025 | uk.finance.yahoo.comVivani Medical shareholders elect board and approve key proposals at annual meeting - Investing.comJune 27, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALUR, VANI, NTRB, and MBOT Company DescriptionsAllurion Technologies NYSE:ALUR$2.11 +0.01 (+0.29%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.Microbot Medical NASDAQ:MBOT$3.52 -0.23 (-6.00%) As of 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Nutriband NASDAQ:NTRB$6.42 +0.26 (+4.13%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Vivani Medical NASDAQ:VANI$1.16 0.00 (0.00%) As of 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
